Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss.
OBJECTIVE
To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.


METHODS
The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).


RESULTS
Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.


CONCLUSIONS
A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.
Dendrinos
S
S
2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece.
Kalogirou
I
I
Makrakis
E
E
Theodoridis
T
T
Mahmound
E A
EA
Christopoulou-Cokkinou
V
V
Creatsas
G
G
D000026:Abortion, Habitual / Q000188:drug therapy*; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000188:drug therapy; D000078222:Tinzaparin
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D001241:Aspirin